Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC
June 30th 2023Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.
Read More
ASCO 2021: New Data for NSCLC Treatment Options
July 22nd 2021Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).
Read More